News

Phase 3 Study to Test 1st Generation Antihistamine EPX-100 in Lennox-Gastaut Syndrome

A new phase 3 study (NCT05066217) will test the efficacy and safety of EPX-100 (Harmony Biosciences), a 1st generation antihistamine agent, as a potential treatment for patients with Lennox-Gastaut syndrome (LGS), a rare epileptic disorder. Overall, the study will enroll patients aged at least 2...

Stephen Hauser Wins Breakthrough Prize for Role in Redefining MS

UCSF Luminary has played a pivotal part in identifying the cause of multiple sclerosis, leading to a new generation of game-changing therapies. 

Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline

 Neurona Therapeutics, a clinical-stage, privately-held, biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, today announced the successful completion of an upsized and oversubscribed $102 million financing.

Enhanced Brain Implant Translates Stroke Survivor’s Thoughts Into Nearly Instant Speech Using Artificial Intelligence

“This is where we are right now,” Edward Chang, a study co-author and neurosurgeon at UC San Francisco, says to the publication. “But you can imagine, with more sensors, with more precision, and with enhanced signal processing, those things are only going to change and get better.”

Montara Therapeutics Closes $20M Oversubscribed Seed Expansion, Appoints Troy Wilson as Chairman of the Board

Montara Therapeutics, a biotech company pioneering brain-selective therapies for CNS diseases, today announced the closing of a $20 million oversubscribed expansion of its Series Seed financing.

Vevo Therapeutics Open Sources Tahoe-100M, the World's Largest Single-Cell Dataset, as the Inaugural Contribution to Arc Institute's New Virtual Cell Atlas

300 million single cell atlas now accessible to the scientific community comprised of Vevo's Tahoe-100M, mapping 60,000 drug-patient interactions, and Arc's AI-curated scBaseCamp 200 million cell dataset. Generated using Vevo's Mosaic platform, Tahoe-100M leveraged Parse Biosciences' GigaLab for...

Junevity Raises $10M to Develop Cell Reset Therapeutics for Longevity

Founded by a team of experts in aging biology, machine learning and drug development and based on pioneering research for resetting cell health by Dr. Janine Sengstack of UCSF. Junevity’s RESET platform uses large-scale human data and AI to identify novel transcription factor targets and repress...

Leveragen Announces Strategic Collaboration with Moonlight Bio to Advance T Cell Therapies Using Proprietary Fully Human Single-Domain Antibody Technology

Leveragen Inc., a Boston-based biotech company specializing in next-generation genetic models for antibody discovery, today announced a strategic collaboration with Moonlight Bio, a Seattle-based biotech company pioneering advanced T-cell therapies. This partnership aims to develop cutting-edge T-...

PreludeDx Receives FDA Breakthrough Device Designation for DCISionRT® Test for DCIS Breast Cancer Patients PreludeDx (PRNewsfoto/PreludeDx)

Prelude Corporation, a leader in precision diagnostics for early-stage breast cancer, announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation for its DCISionRT® test. Thea Tlsty is the lead UCSF inventor. MORE

Venova Medical Announces First Subjects Enrolled in VENOS-2 IDE Study of the Velocity Percutaneous AVF System

The VENOS-2 prospective, multicenter study is being performed under an Investigational Device Exemption (IDE) granted by the FDA and will evaluate the feasibility of the company's Velocity pAVF System which is designed to enable a minimally invasive approach for the creation of an AV fistula for...